XIFAXAN

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Hong Kong SAR China, Malta, Netherlands, New Zealand, Poland, Singapore.

Active ingredients

The drug XIFAXAN contains one active pharmaceutical ingredient (API):

1	Rifaximin UNII L36O5T016N - RIFAXIMIN
	Rifaximin is an antibacterial agent of the rifamycin class that inhibits bacterial RNA synthesis. Rifaximin has a broad antimicrobial spectrum against most of the Gram-positive and -negative, aerobic and anaerobic bacteria responsible for intestinal infections.
	Read more about Rifaximin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XIFAXAN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07AA11	Rifaximin	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07A Intestinal antiinfectives → A07AA Antibiotics
Discover more medicines within A07AA11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10001J
BR	Câmara de Regulação do Mercado de Medicamentos	504120070069507, 504120070069607, 504120070069707
HK	Department of Health Drug Office	61689
MT	Medicines Authority	AA565/61701
NL	Z-Index G-Standaard, PRK	105430
NZ	Medicines and Medical Devices Safety Authority	15765
PL	Rejestru Produktów Leczniczych	100041059, 100136529, 100203600, 100257606, 100264486, 100286832, 100375085, 100386692, 100398442, 100416542, 100416938, 100417323, 100417636, 100439402
SG	Health Sciences Authority	14761P
US	FDA, National Drug Code	55154-6777, 65649-301, 65649-303